Skip to Content
Merck
All Photos(1)

Key Documents

A9950

Sigma-Aldrich

Aniracetam

≥98%

Synonym(s):

1-(4-Methoxybenzoyl)-2-pyrrolidinone, Ro 13-5057

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C12H13NO3
CAS Number:
Molecular Weight:
219.24
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

Pricing and availability is not currently available.

Assay

≥98%

originator

Roche

SMILES string

COc1ccc(cc1)C(=O)N2CCCC2=O

InChI

1S/C12H13NO3/c1-16-10-6-4-9(5-7-10)12(15)13-8-2-3-11(13)14/h4-7H,2-3,8H2,1H3

InChI key

ZXNRTKGTQJPIJK-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Application

Aniracetam has been used in the inhibition screening assays for kinase enzyme.[1]

Biochem/physiol Actions

Aniracetam is a piracetam analog and has low bioavailability due to rapid excretion.[2] It enhances the cognitive thinking and is effective for treatment of sleep and behavioral disorders.[3] Aniracetam is prescribed for anxiety and also enhances learning and memory in situations with induced damage of the brain.[4]
Cognition enhancer (nootropic) that potentiates AMPA receptor mediated ion conductance and potentiates metabotropic glutamate receptor activity.

Features and Benefits

This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Chrysi C Koliaki et al.
CNS neuroscience & therapeutics, 18(4), 302-312 (2011-11-11)
Dementia constitutes an increasingly prevalent cognitive disorder with serious socioeconomic implications. In the present study, we aimed to evaluate the efficacy of aniracetam, either as monotherapy or combined with cholinesterase inhibitors (ChEIs), in terms of several neuropsychological parameters, in a
A Pittaluga et al.
Naunyn-Schmiedeberg's archives of pharmacology, 359(4), 272-279 (1999-05-27)
Aniracetam, 1-(1,3-benzodioxol-5-yl-carbonyl)piperidine (1-BCP) and cyclothiazide, three compounds considered to enhance cognition through modulation of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors, were evaluated in the 'kynurenate test', a biochemical assay in which some nootropics have been shown to prevent the antagonism by kynurenic
Tatiana Lipina et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 32(4), 745-756 (2006-08-29)
In order to test the possible role of mGluR5 signaling in the behavioral endophenotypes of schizophrenia and other psychiatric disorders, we used genetic engineering to create mice carrying null mutations in this gene. Compared to their mGluR5(+/+) littermates, mGluR5(-/-) mice
Idebenone is a cytoprotective insulin sensitizer whose mechanism is Shc inhibition.
Tomilov A, et al.
Pharmacological Research, 137(8), 89-103 (2018)
Kazuo Nakamura
CNS drug reviews, 8(1), 70-89 (2002-06-19)
Aniracetam is a pyrrolidinone-type cognition enhancer that has been clinically used in the treatment of behavioral and psychological symptoms of dementia following stroke and in Alzheimer's disease. New discoveries in the behavioral pharmacology, biochemistry and pharmacokinetics of aniracetam provided new

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service